Skip to main content

Table 4 The PK-PD model of FF, DoxHcl and DoxHcl&FF ex vivo

From: The dose regimen formulation of doxycycline hydrochloride and florfenicol injection based on ex vivo pharmacokinetic-pharmacodynamic modeling against the Actinobacillus pleuropneumoniae in pigs

Parameters

Unit

Healthy (FF)

Diseased (FF)

Healthy (DoxHcl)

Diseased (DoxHcl)

Emax

logCFU/mL

2.23 ± 0.006

2.41 ± 0.002

2.00 ± 0.001

2.40 ± 0.004

EC50

h

8.55 ± 0.22

9.94 ± 0.36

6.58 ± 0.35

11.55 ± 0.61

E0

logCFU/mL

−5.52 ± 0.03

− 5.27 ± 0.03

−6.85 ± 0.36

−5.16 ± 0.04

N

–

1.17 ± 0.04

1.36 ± 0.038

0.58 ± 0.07

1.73 ± 0.13

(AUC0-24h/MIC)ex(E = 0)

h

3.94 ± 0.22

5.61 ± 0.26

0.78 ± 0.24

7.42 ± 0.64

(AUC0-24h/MIC)ex(E = − 3)

h

15.99 ± 0.28

18.83 ± 0.49

10.32 ± 0.73

19.64 ± 0.53

(AUC0-24h/MIC)ex(E = − 4)

h

28.63 ± 0.21

32.68 ± 0.64

24.06 ± 0.48

31.08 ± 0.38

  1. (AUC24h/MIC)ex E represents the difference of bacteria logarithmic between the initial inoculated bacteria and the alveolar fluid sample at different time points cultivated for 24 h; E0 represents the difference of bacteria logarithmic between the initial inoculated bacteria and the alveolar fluid sample cultivated for 24 h; Emax represents the difference of bacteria logarithmic between the initial inoculated bacteria and the blank alveolar fluid cultivated for 24 h; EC50 represents the PK-PD parameter in ex vivo when the half of the maximum effect of alveolar fluid sample was produced; N represents the Hill coefficient, describing the PK-PD parameter in the half body and the slope after linearization with the effect of E